Effects of dietary fat structure on fat deposition in healthy Australian adults

Not Applicable

Completed

• Conditions: Cardio-metabolic disease; Non-alcoholic Fatty Liver Disease (NAFLD); Obesity; Cardiovascular disease; Diet and Nutrition - Obesity; Metabolic and Endocrine - Diabetes; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12618000201279
• Lead Sponsor: CSIRO Health and Biosecurity

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-02-07
• Study Completion: 2018-12-14
• Last Update Posted: 28 January 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

1.Healthy adults
2.BMI 18.5-27.5 kg/m2
3.Understand the study requirements and willing to adhere closely to prescribed food consumption as per the research protocol

Exclusion Criteria

1.Self-reported history of any of the following chronic diseases - type 2 diabetes, hypertension, coronary heart disease, hyperlipidemia, liver disease, cancer (excluding skin cancer), haemochromatosis
2.Self-reported history of pancreatic insufficiency or other conditions resulting in fat malabsorption - chronic pancreatitis, cystic fibrosis, coeliac disease, Crohns disease, gastric bypass surgery, small bowel resection, abnormal thyroid function
3.On medication/nutraceuticals that may affect liver function, blood lipids, blood pressure or body weight, as assessed by the Principal Investigator or designee
4.Self-reported history of claustrophobia – to enable MRS/MRI assessments to be performed
5.Presence of any ferrous metal in the body - to enable MRS/MRI assessments to be performed.
6.Self-reported pregnant or currently lactating women
7.Females who are post-menopausal, on hormone replacement therapy or on hormone based contraceptives, unless they are stable for at least 3 months prior to study commencement (no changes in type and dose) and have no intention to change during study
8.History of smoking during the 6 months prior to the study
9.Alcohol consumption >21 units per week for men & >14 units per week for women
10.Mean blood pressure >140/90 mmHg assessed at screening visit
11.Hyperlipidemia (fasting TC>6.2 mmol/L or TAG >2.0 mmol/L) assessed at screening visit
12.Abnormal serum liver enzymes (ALT, AST) assessed at screening visit
13.Extended absences due to travel or other commitments
14.Self-reported known allergies to intervention foods
15.On any weight-loss program

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
iver fat content as measured by proton magnetic resonance spectroscopy (MRS)[Weeks 0 and 16]